Answers are grounded in this paper and cite their sources.
The current treatment of hemophilia, whether due to a deficiency of factor VIII or factor IX — as reviewed in this issue of the Journal 1 — consists of periodic replacement of the deficient factor with human blood products or recombinant proteins that have been synthesized in tissue culture. Ideally, there should be continuous endogenous production of these factors to protect against bleeding and to minimize exposure to infectious agents that may be present in replacement therapies. Theoretically, this goal can be achieved with gene therapy. The hemophilias are attractive candidates for gene therapy: the wide range of serum levels of . . .
No takes yet. Share an insight, caveat, or question.
Miller et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: